| Helix BioPharma Corp. is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapeutics. Helix's business model is to commercialize the new products that result from our development efforts by establishing strategic licensing arrangements with market leaders in the appropriate therapeutic fields.
Established by amalgamation in 1995, Helix is publicly listed, with its common shares traded on the Toronto Stock Exchange. In addition, the Corporation is quoted on the Frankfurt, Munich, Stuttgart and Berlin stock exchanges. Helix's trading symbol is "HBP."
|
Search Product